All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

^{*Sheetz looks to be the dominant convenience store chain in Pennsylvania, hence the gif - let me know if I’m wrong on this!}

THE GOOD
Approvals & Labels

Sanofi's Rezurock (belumosudil) receives CHMP approval recommendation for chronic graft-versus-host disease treatment
Small molecule, autoimmune, chronic graft-versus-host disease, ROCK2 kinase inhibitor, post-transplant complications - Read more

Incyte's Zynyz (retifanlimab) receives positive CHMP opinion for first-line advanced squamous cell carcinoma of anal canal
Antibody, cancer, monoclonal antibody, PD-1 inhibitor, combination therapy - Read more

CHMP recommends Novo Nordisk's semaglutide for MASH approval in Europe as Kayshild
GLP-1 agonist, metabolic disease, regulatory, strategic - Read more

THE GOOD
Business Development & Partnerships

Moderna, Recordati partner on rare disease mRNA therapy mRNA-3927, $50M upfront, $110M milestones
Licensing deal, rare disease, mRNA therapy, milestone payments - Read more

AstraZeneca, CSPC Pharmaceutical partner on obesity drugs, $1.2B upfront, $18.5B total potential
Licensing deal, obesity, GLP-1 receptor agonist, milestone payments, AI-driven drug discovery - Read more

Samsung Bioepis reaches settlement with Regeneron, Bayer for Eylea biosimilar launch in Europe from 2026
Licensing deal, ophthalmology, biosimilar, settlement agreement - Read more

Ipsen, Origami Therapeutics collaborate on protein degrader program targeting genetic neurodegenerative diseases with milestone payments
Research collaboration, rare disease, neurological, small molecule, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Regeneron Pharmaceuticals beats Q4 profit estimates driven by strong Dupixent eczema treatment sales growth
Monoclonal antibody, autoimmune, financial, competitive - Read more

THE GOOD
Fundraises

Lexicon Pharmaceuticals raises $94.6M public offering for drug candidate R&D
Pharmaceutical, drug development, clinical-stage, small molecule - Read more

ProMIS Neurosciences raises $175M private placement, neurodegenerative disease antibody therapeutics
Neurological, antibody, clinical-stage, Alzheimer disease - Read more

Yosemite plans for $350M Fund II, cancer research investment firm
Cancer, investment firm - Read more

THE GOOD
Investments

Eli Lilly picks Pennsylvania for fourth US manufacturing site in $27B domestic expansion push
Small molecule, obesity, operational, major transaction - Read more

CDMO Vetter Pharma invests €480M ($574.4M) for new German production facility, targeting 2031 launch with 2,000 jobs
Biologics manufacturing, operational, major investment, capacity expansion - Read more

THE GOOD
Politics & Policy

HHS Secretary Kennedy appoints Michelle Branham as new Chair of Federal Alzheimer's Advisory Council
Neurological, strategic, operational, regulatory - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Amgen returns rocatinlimab eczema drug rights to Kyowa Kirin following strategic portfolio prioritization
Licensing deal, autoimmune, antibody, strategic portfolio prioritization - Read more

THE BAD
Earnings & Finances

Regeneron expects Eylea franchise sales decline to continue in Q1 despite Eylea HD growth
Monoclonal antibody, ophthalmology, financial, revenue impact - Read more

THE BAD
Layoffs

CRO Sygnature Discovery plans to lay off 60 UK employees amid competitive market conditions
Drug discovery services, operational, cost reduction, competitive pressures - Read more

THE BAD
Politics & Policy

White House delays TrumpRx launch amid anti-kickback concerns, platform expected online within 10 days
Direct-to-consumer sales, regulatory, operational, cost reduction - Read more

THE BAD
Regulatory

Corcept Therapeutics shares fall 17% after FDA reportedly warned against submitting relacorilant drug application multiple times
Small molecule, rare disease, regulatory, financial - Read more

EMA reviews Amgen's Tavneos approval amid data integrity concerns from ADVOCATE trial study
Small molecule, autoimmune, regulatory, strategic - Read more

UK MHRA warns GLP-1 weight-loss drug users of small severe acute pancreatitis risk
GLP-1 agonist, metabolic disease, regulatory, safety - Read more

THE BAD
Strategic Plans

Chugai Pharmaceutical drops AI-assisted antibody BRY10 from pipeline but remains committed to Malexa technology platform
Monoclonal antibody, chronic disease, strategic, operational - Read more

THE UGLY
Politics & Policy

Trump administration officials clash over potential removal of COVID-19 vaccines from U.S. market amid policy disagreements
mRNA vaccine, infectious disease, regulatory, strategic - Read more

Rare disease priority review voucher program reauthorization delayed amid Senate immigration funding dispute
Antisense oligonucleotide, rare disease, regulatory, financial - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here